Plasma Fractionation Market to Reach USD 38.65 Bn by 2026, Kedrion Biopharma’s FDA Approval to Create Attractive Growth Opportunities: Fortune Business Insights

    NEXT STORY
    Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019
    PREV STORY
    Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

    author_avatar
    NASDAQ Market News

    Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial

    CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology ...

    author_avatar
    NASDAQ Market News

    Basilea reports 2016 half-year results – CRESEMBA(R) launched in key European markets

    Antifungal CRESEMBA® (isavuconazole) launched in first European markets Entered contract with BARDA for the ...

    author_avatar
    NASDAQ Market News